Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

BZAM Ltd. BZAMF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score
37/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

BZAM Ltd. (BZAMF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 35/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $49M, +72.3%/yr average growth. Net income is $36M (loss), growing at +33%/yr. Net profit margin is -71.9% (negative). Gross margin is 13.7% (-73.4 pp trend).

Balance sheet: total debt is $45M against $172M equity (Debt-to-Equity (D/E) ratio 0.26, conservative). Current ratio is 2.08 (strong liquidity). Debt-to-assets is 16.3%. Total assets: $274M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 7/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

BZAMF SharesGrow Score Overview

46/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 7/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BZAMF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
BZAMF: +72.3%/yr revenue is, +33%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet BZAMF: Debt-to-Equity (D/E) ratio 0.26 (conservative), Current ratio is 2.08 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
7/100
BZAMF: Gross margin is 13.7% (-73.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 7/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
BZAMF: Net profit margin is -71.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.00001-0.001
Volume11.5K
Avg Volume (30D)204
Market Cap$2.71K
Beta (1Y)2.27
Share Statistics
EPS (TTM)-0.41
Shares Outstanding$86.53M
IPO Date2018-05-03
CEOMatt Milich
Financial Highlights & Ratios
Revenue (TTM)$49.35M
Gross Profit$6.75M
EBITDA$-21.09M
Net Income$-35.5M
Operating Income$-35.24M
Total Cash$4.65M
Total Debt$44.68M
Net Debt$40.03M
Total Assets$274.44M
Price / Earnings (P/E)-0
Price / Sales (P/S)0
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA12464X1015

Price Chart

Track all markets on TradingView
BZAMF
BZAM Ltd. ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
0.00 52WK RANGE 0.00

People Also View

LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
 RHHBF
RHHBF
Roche Holding AG
$415.00
-0.84%
 RHHBY
RHHBY
Roche Holding AG
$50.99
-0.08%
 AZN
AZN
AstraZeneca PLC
$201.21
-1.55%
 NVS
NVS
Novartis AG
$152.08
-0.85%
 MRK
MRK
Merck & Co., Inc.
$117.90
-1.72%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message